Search

Your search keyword '"Hui-Ying Hsu"' showing total 2 results
Start Over Author "Hui-Ying Hsu" Publisher mdpi ag
2 results on '"Hui-Ying Hsu"'

1. Metformin Increases Survival in Hypopharyngeal Cancer Patients with Diabetes Mellitus: Retrospective Cohort Study and Cell-Based Analysis

Author

Yung-An Tsou, Wei-Chao Chang, Chia-Der Lin, Ro-Lin Chang, Ming-Hsui Tsai, Liang-Chun Shih, Theresa Staniczek, Tsu-Fang Wu, Hui-Ying Hsu, Wen-Dien Chang, Chih-Ho Lai, and Chuan-Mu Chen

Subjects
hypopharyngeal squamous cell carcinoma, metformin, drug repositioning, anticancer, mortality, autophagy, Medicine, Pharmacy and materia medica, RS1-441
Abstract

Hypopharyngeal squamous cell carcinoma (HSCC) is usually diagnosed at an advanced stage, leading to a poor prognosis. Even after improvement of surgical techniques, chemotherapy, and radiation technology, the survival rate of HSCC remains poor. Metformin, which is commonly used for type 2 diabetes mellitus (DM), has been suggested to reduce the risk of various cancer types. However, only a few clinical studies mentioned the relationship between metformin use and HSCC. Hence, the aim of this study was to elucidate the specific effect and mechanism of action of metformin in hypopharyngeal cancer. We first assessed whether metformin use has an effect on hypopharyngeal cancer patients with DM by conducting a retrospective cohort study. Our results showed that DM hypopharyngeal cancer patients who used metformin exhibited significantly better overall survival rates than that without metformin treatment. The cell-based analysis further indicated that metformin treatment regulated p38/JNK pathway to reduce Cyclin D1 and Bcl-2 expressions. In addition, metformin activated the pathways of AMPKα and MEK/ERK to phosphorylate p27(Thr198) and reduce mTOR phosphorylation in cells. These actions direct cells toward G1 cell cycle arrest, apoptosis, and autophagy. Our results, through combining a clinical cohort analysis with an in vitro study, demonstrate that metformin can be used for drug repositioning in the treatment of DM patients with hypopharyngeal cancer.

Published
2021
Full Text
View/download PDF

2. Probiotic Lactobacillus spp. act Against Helicobacter pylori-induced Inflammation

Author

Wei Wei Chen, Wen Ling Yeh, Hsin-Chih Lai, Yu Hsin Lin, Wen-Wei Chang, Ya Hui Chen, Chih Ho Lai, Tzu Lung Lin, Hui Yu Wu, Yu Wen Chen, Tsai Wan Hua, Chen Yi Hsing, Chun Ya Chen, and Hui Ying Hsu

Subjects
lcsh:Medicine, Microbiology, law.invention, 03 medical and health sciences, Probiotic, 0302 clinical medicine, Lactobacillus acidophilus, Lactobacillus rhamnosus, law, Lactobacillus, Medicine, 030304 developmental biology, Bifidobacterium, 0303 health sciences, biology, Helicobacter pylori, business.industry, lcsh:R, food and beverages, Akkermansia, General Medicine, biology.organism_classification, Multiple drug resistance, inflammation, 030211 gastroenterology & hepatology, business, probiotic
Abstract

The bacterial species, Helicobacter pylori, is associated with several gastrointestinal diseases, and poses serious health threats owing to its resistance to antibiotics. Lactobacillus spp., on the other hand, possess probiotic activities that have beneficial effects in humans. However, the mechanisms by which Lactobacillus spp. harbor favorable functions and act against H. pylori infection remain to be explored. The aim of this study was to investigate the ability of bacterial strains, Lactobacillus rhamnosus and Lactobacillus acidophilus, termed GMNL-74 and GMNL-185, respectively, to inhibit H. pylori growth and inflammation. Our results showed that GMNL-74 and GMNL-185 possess potent antimicrobial activity against multidrug resistant (MDR)-H. pylori. In addition, an in vitro cell-based model revealed that the inhibition of H. pylori adhesion and invasion of gastric epithelial cells and interleukin-8 production were significantly decreased by treatment with both the Lactobacillus strains. In vivo studies demonstrated that colonization of H. pylori and induced inflammation in the mouse stomach were also alleviated by these Lactobacillus strains. Furthermore, the abundance of beneficial gut bacteria, including Bifidobacterium spp. and Akkermansia muciniphilia, were significantly increased in H. pylori-infected mice treated with GMNL-74 and GMNL-185. These results demonstrate that Lactobacillus spp. ameliorate H. pylori-induced inflammation and supports beneficial gut specific bacteria that act against H. pylori infection.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results